- |||||||||| everolimus / Generic mfg.
Challenges in the Management of Giant Bilateral Renal Angiomyolipomas in a Young Woman with Tuberous Sclerosis Complex: A Case Report (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3703;
After a multidisciplinary conference and discussion with the patient and her family, conservative management and therapy with mTOR inhibitor everolimus were pursued...mTOR inhibition is employed to retard tumor size and growth and reduce the risk for bleeding. The challenge with managing such cases requires a multidisciplinary approach and shared decision-making to arrive at the best patient-centered outcomes.
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Rapid Acute Rejection with Cortical Necrosis after First-Dose Cemiplimab in a Living Donor Kidney Transplant (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3425;
However, a recent prospective study using CPM showed safe use in TR with sirolimus (SRL).Case Description: A 71-year-old male, CKD/V due to IgA nephropathy received a living donor TR...He received basiliximab induction and maintained on a standard IS of tacrolimus (TAC), mycophenolate (MMF), and prednisone...By 8 Ms PTx, he had CMV disease so everolimus was held kept him on prednisone and TAC...Our patient suffered from a rapid aggressive acute rejection at 1 week after first dose of CMP that resulted in cortical necrosis and graft loss. This is the first case of rapid renal allograft loss due to acute rejection and cortical necrosis after the CMP reported in literature.
- |||||||||| everolimus / Generic mfg.
An Unusual Case of Lymphangioma-Like Kaposi Sarcoma in a Kidney Transplant Patient (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3389;
Tacrolimus was changed to everolimus with improvement and stabilization of the Kaposi's lesions LLKS is a rare histologic presentation of KS which is strongly associated with HHV-8 infection. Incidence of Kaposi sarcoma in renal transplant is 1.5%, however the incidence of LLKS in renal transplant patient is extremely rare.mTOR inhibits the HHV-8 lytic replication cycle and has an antineoplastic and antiangiogenic effects.This case report represents further evidence of the utility of an mTOR inhibitor as a treatment for kidney transplant
- |||||||||| Vistide (cidofovir) / Gilead
A Rare Cause of Kidney Failure: Native Kidney BK Polyomavirus Nephropathy after Lung Transplant (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2288;
We present a case of native kidney BKVN leading to end-stage kidney disease (ESKD) in a lung transplant recipient.Case Description: A 71-year-old woman with history of obliterative bronchiolitis who received a bilateral lung transplant in 2021 (on everolimus, mycophenolate mofetil, and prednisone) with course complicated by ischemic stroke, intermittent hypotension, and frequent urinary tract infections was referred to the renal clinic with progressive renal failure in 2023...She was started on cidofovir and, though her BK serum viral load improved, her renal function deteriorated and she developed ESKD...Viral inclusions within the tubuler epithelial cells. Postive SV40 staining of tubular epithelial cells.
- |||||||||| cisplatin / Generic mfg., everolimus / Generic mfg., irinotecan / Generic mfg.
Journal: Primary Neuroendocrine Carcinoma of the Ileum With Markedly Elevated Carcinoembryonic Antigen (CEA) Levels: A Case Report. (Pubmed Central) - Sep 12, 2024
Initial chemotherapy with irinotecan, cisplatin (IP), and octreotide acetate proved ineffective...Switching to everolimus as second-line therapy temporarily decreased CEA levels and tumor size, but the disease progressed with cervical lymph node involvement...Necropsy of the cervical lymph nodes was consistent with the original surgical findings. This case highlights the aggressive nature and challenging management of NEC with significantly elevated CEA levels.
- |||||||||| Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Review, Journal: Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients. (Pubmed Central) - Sep 11, 2024
For decades, CMV management after transplantation has relied on antiviral drugs that inhibit viral DNA polymerase (ganciclovir, foscarnet, and cidofovir)...However, letermovir and maribavir have a significant drug interaction potential in solid organ transplant recipients, resulting in higher levels of calcineurin inhibitors (cyclosporine and tacrolimus) and mTOR inhibitors (sirolimus and everolimus)...This article provides a comprehensive review of the clinical data supporting the use of letermovir and maribavir in clinical practice. The author provides perspectives on the role of these newly approved drugs in the current management landscape of CMV infection in solid organ transplantation.
- |||||||||| everolimus / Generic mfg.
RETROPERITONEAL HEMATOMA: AN UNEXPECTED COMPLICATION OF TUBEROUS SCLEROSIS AND LYMPHANGIOLEIOMYOMATOSIS (Convention Center Exhibit Hall: Poster Area 4) - Sep 11, 2024 - Abstract #CHEST2024CHEST_7089;
This approach is crucial for ensuring the long-term well-being and quality of life for individuals affected by TSC. This case highlights the need for high clinical suspicion of hemorrhage arising from pre-existing RAMLs in patients with LAM who present with evidence of a sudden drop in Hgb.
- |||||||||| Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Review, Journal: Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) - Sep 10, 2024
The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.
- |||||||||| Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Journal: Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) - Sep 10, 2024
The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.
- |||||||||| Welireg (belzutifan) / Merck (MSD)
FDA event, Journal, Metastases: FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. (Pubmed Central) - Sep 9, 2024
P3
The confirmed objective response rate by BICR was 22% and 3.6% in belzutifan and everolimus arms, respectively. Observed toxicities differed between treatment arms, but drug discontinuations and interruptions due to treatment-emergent adverse events were lower on the belzutifan arm compared to the everolimus arm, and a descriptive analysis of patient-reported symptom and functional outcomes was suggestive of favorable tolerability for belzutifan compared to everolimus.
- |||||||||| imlunestrant (LY3484356) / Eli Lilly
P1 data, Journal, Combination therapy, Monotherapy, Metastases: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. (Pubmed Central) - Sep 6, 2024
All other abstracts will be released on the day of presentation. Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2- ABC.
- |||||||||| Torisel (temsirolimus) / Pfizer
Journal: Characterization of effects of mTOR inhibitors on aging in C. elegans. (Pubmed Central) - Sep 5, 2024
As in mouse, rapamycin had mixed effects on age-related pathologies, inhibiting one (uterine tumor growth) but not several others, suggesting a segmental antigeroid effect. These findings should usefully inform future experimental studies with rapamycin and rapalogs in C. elegans.
- |||||||||| everolimus / Generic mfg., dasatinib / Generic mfg.
LOXL2 as a Potential Therapeutic Target in Primary Myelofibrosis (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_680;
The findings suggest that LOXL2 plays a critical role in the pathogenesis of PMF by modulating these pathways. The identification of potential targeted drugs for LOXL2, such as dasatinib, everolimus, and simvastatin, opens new avenues for the development of personalized therapeutic approaches in the management of PMF.
- |||||||||| everolimus / Generic mfg.
Enrollment open: ELIMINATE: Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (clinicaltrials.gov) - Aug 28, 2024
P2, N=340, Recruiting,
The identification of potential targeted drugs for LOXL2, such as dasatinib, everolimus, and simvastatin, opens new avenues for the development of personalized therapeutic approaches in the management of PMF. Not yet recruiting --> Recruiting
- |||||||||| Tazverik (tazemetostat) / Eisai, Ipsen, Torisel (temsirolimus) / Pfizer
Journal, Epigenetic controller: CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. (Pubmed Central) - Aug 27, 2024
Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and describe distinct transcriptional characteristics and co-occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.
- |||||||||| Retrospective data, Journal: The Consequences of HLA Screening in the Prevention of Graft-Versus-Host Disease in Living Donor Liver Transplantation. (Pubmed Central) - Aug 23, 2024
We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and describe distinct transcriptional characteristics and co-occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL. The results support the policy of avoiding HLA combinations that preclude immune recognition of graft lymphocytes as foreign to decrease the risk of GVHD after LDLT.
- |||||||||| methamphetamine / Generic mfg.
Methamphetamine and sucrose craving incubate regardless of systemic mTOR inhibition (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_7305;
Further, our results indicate that, in contrast to cocaine, mTOR activity is not required for the incubation of either methamphetamine or sucrose craving, arguing against heightened mTOR activity as a biochemical driver of incubation of craving per se. Taken together, our collection of data support the potential clinical utility of Everolimus for mitigating incubated cocaine, but not methamphetamine, craving during protracted withdrawal and provide evidence to support no overt effect of Everolimus on the conditioned reinforcing properties of non-drug reinforcers of relevance to off-target motivational effects.
- |||||||||| everolimus / Generic mfg., nimodipine / Generic mfg.
Treatment of aggressive meningioma cells with mibefradil leads to up-regulation of L-type channels supporting neoplastic progression (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_42;
Medical therapies for WHO grade III meningiomas are limited; avastin, everolimus, mifepristone, octreotide, and hydroxyurea (HU) are currently used off-label to treat unresectable progressive or recurrent WHO grade III meningiomas...Moreover, blockade of T-type VGCCs with clinically relevant concentrations of mibefradil (MIB) or nimodipine (NIMO) decreases cell viability and proliferation to a similar degree as HU, demonstrating their importance...Interlaced treatment displayed less efficacy than CT overall. The use of FDA-approved VGCC antagonists in combination with HU could be a promising avenue for the treatment of malignant MN.
- |||||||||| Welireg (belzutifan) / Merck (MSD)
Clinical, Journal, Metastases: Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. (Pubmed Central) - Aug 21, 2024
P3
Belzutifan was associated with no new safety signals. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; LITESPARK-005 ClinicalTrials.gov number, NCT04195750.).
- |||||||||| Cabometyx (cabozantinib tablet) / Exelixis
Retrospective data, Review, Journal, Metastases: The efficacy and safety of cabozantinib in patients with metastatic or advanced renal cell carcinoma: a systematic review and meta-analysis. (Pubmed Central) - Aug 21, 2024
However, in subgroup analyses, cabozantinib was only statistically superior to everolimus...Cabozantinib shows significant efficacy in extending overall survival, progression-free survival, and tumor objective response rate despite a potentially higher risk of adverse events compared to sunitinib. These findings support cabozantinib as a first-line therapy for aRCC, either as an initial treatment or after prior VEGFR-targeted therapies.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
A Rare Case of Angiosarcoma in Patients With Liver Transplant (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5254;
He then opted for comfort care and eventually passed away three months after the diagnosis AS is a highly aggressive rare tumor reported in renal tx recipients. Its clinical course and management strategies in liver tx pts post-LT remain understudied and requires further research.
- |||||||||| Envarsus (LCP-Tacro) / Asahi Kasei
A Global Comparison of Liver Transplant Drug Pricing: US vs the G7 Countries and Australia (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5122;
Its clinical course and management strategies in liver tx pts post-LT remain understudied and requires further research. Publicly available drug formularies for Canada, UK, Japan, France, Germany, Italy, and Australia were used to collect 2024 prices for 8 commonly used liver transplant immunosuppressive medications (mycophenolate mofetil, mycophenolate sodium, sirolimus, tacrolimus, Advagraf
- |||||||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
A Rare Case of B-Cell Lymphoma Diagnosed in an Explanted Liver in a Patient With MASH Cirrhosis! (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3647;
Immunostains reveal the diffuse infiltrate to express C20 (shown below), CD5 (shown below), PAX5, and CD43. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
- |||||||||| everolimus / Generic mfg.
Effect of Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Upon Skin and Other Malignancy Following Liver Transplantation (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3385;
25 patients in group 1 (9.7%), 4 in group 2 (6.8%) and 6 (9.2%) in group 3 developed some skin malignancy with squamous cell carcinoma the most common among all three groups (group 1 vs 3, p =0.835; group 2 vs 3, p =0.513). 26 patients in group 1 (10.1%), 6 in group 2 (6.8%) and 5 (7.7%) developed some other type of malignancy, and among other malignancies, hematologic was most common in group 1 (n=6, 23%) and non-hepatic gastrointestinal was most common in group 2 (n=4, 67%) and 3 (n=4, 80%).
|
